(Q40284336)

19 September 2017

title

Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer (English)

1 reference

triple-negative breast cancer

19 September 2017

0 references

0 references

A Vingiani

2

0 references

author name string

G Pruneri

1

1 reference

19 September 2017

V Bagnardi

3

1 reference

19 September 2017

N Rotmensz

4

1 reference

19 September 2017

A De Rose

5

1 reference

19 September 2017

A Palazzo

6

1 reference

19 September 2017

A M Colleoni

7

1 reference

19 September 2017

A Goldhirsch

8

1 reference

19 September 2017

G Viale

9

1 reference

19 September 2017

publication date

23 November 2015

1 reference

19 September 2017

1 reference

19 September 2017

volume

27

1 reference

19 September 2017

issue

2

1 reference

19 September 2017

page(s)

249-256

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Immune infiltration in human tumors: a prognostic factor that should not be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Statistical methods for assessing agreement between two methods of clinical measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Clinical overview of metronomic chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV571

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV571

1 reference

19 September 2017

1 reference